These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 24566733

  • 1. Aspirin decreases systemic exposure to clopidogrel through modulation of P-glycoprotein but does not alter its antithrombotic activity.
    Oh J, Shin D, Lim KS, Lee S, Jung KH, Chu K, Hong KS, Shin KH, Cho JY, Yoon SH, Ji SC, Yu KS, Lee H, Jang IJ.
    Clin Pharmacol Ther; 2014 Jun; 95(6):608-16. PubMed ID: 24566733
    [Abstract] [Full Text] [Related]

  • 2. Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response.
    Gong IY, Crown N, Suen CM, Schwarz UI, Dresser GK, Knauer MJ, Sugiyama D, DeGorter MK, Woolsey S, Tirona RG, Kim RB.
    Eur Heart J; 2012 Nov; 33(22):2856-2464a. PubMed ID: 22374717
    [Abstract] [Full Text] [Related]

  • 3. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function.
    Frelinger AL, Bhatt DL, Lee RD, Mulford DJ, Wu J, Nudurupati S, Nigam A, Lampa M, Brooks JK, Barnard MR, Michelson AD.
    J Am Coll Cardiol; 2013 Feb 26; 61(8):872-9. PubMed ID: 23333143
    [Abstract] [Full Text] [Related]

  • 4. Clopidogrel pharmacodynamics and pharmacokinetics in the fed and fasted state: a randomized crossover study of healthy men.
    Hurbin F, Boulenc X, Daskalakis N, Farenc C, Taylor T, Bonneau D, Lacreta F, Cheng S, Sultan E.
    J Clin Pharmacol; 2012 Oct 26; 52(10):1506-15. PubMed ID: 22128201
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of ADP-induced platelet aggregation by clopidogrel is related to CYP2C19 genetic polymorphisms.
    Chen BL, Zhang W, Li Q, Li YL, He YJ, Fan L, Wang LS, Liu ZQ, Zhou HH.
    Clin Exp Pharmacol Physiol; 2008 Aug 26; 35(8):904-8. PubMed ID: 18346178
    [Abstract] [Full Text] [Related]

  • 6. CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients.
    Hulot JS, Collet JP, Cayla G, Silvain J, Allanic F, Bellemain-Appaix A, Scott SA, Montalescot G.
    Circ Cardiovasc Interv; 2011 Oct 01; 4(5):422-8. PubMed ID: 21972404
    [Abstract] [Full Text] [Related]

  • 7. The genetic basis of platelet responsiveness to clopidogrel. A critical review of the literature.
    Fefer P, Matetzky S.
    Thromb Haemost; 2011 Aug 01; 106(2):203-10. PubMed ID: 21792462
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Genetic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects.
    Simon T, Bhatt DL, Bergougnan L, Farenc C, Pearson K, Perrin L, Vicaut E, Lacreta F, Hurbin F, Dubar M.
    Clin Pharmacol Ther; 2011 Aug 01; 90(2):287-95. PubMed ID: 21716274
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Impact of P-glycoprotein on clopidogrel absorption.
    Taubert D, von Beckerath N, Grimberg G, Lazar A, Jung N, Goeser T, Kastrati A, Schömig A, Schömig E.
    Clin Pharmacol Ther; 2006 Nov 01; 80(5):486-501. PubMed ID: 17112805
    [Abstract] [Full Text] [Related]

  • 16. High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2).
    Collet JP, Hulot JS, Anzaha G, Pena A, Chastre T, Caron C, Silvain J, Cayla G, Bellemain-Appaix A, Vignalou JB, Galier S, Barthélémy O, Beygui F, Gallois V, Montalescot G, CLOVIS-2 Investigators.
    JACC Cardiovasc Interv; 2011 Apr 01; 4(4):392-402. PubMed ID: 21511218
    [Abstract] [Full Text] [Related]

  • 17. The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects.
    Umemura K, Furuta T, Kondo K.
    J Thromb Haemost; 2008 Aug 01; 6(8):1439-41. PubMed ID: 18532997
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.